SION Stock: Insider Activity, Filings & Research

Sionna Therapeutics, Inc. (SION) — Drillr’s hub for SION insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, SION insiders filed 0 open-market buys and 18 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$77.6M

Insider trades by month Buys Sells

Dec

Jan

Feb

Mar

Apr

May

Context3-month price +6.2%Institutions accumulating (13F)

Date	Insider	Type	Shares	Price
May 29, 2026	ORBIMED ADVISORS LLCdirector	Sell	101	$44.49
May 29, 2026	Thompson Peter A.director	Sell	101	$44.49
May 11, 2026	ORBIMED ADVISORS LLCdirector	Sell	48,546	$44.61
May 11, 2026	Thompson Peter A.director	Sell	184,639	$46.22
May 11, 2026	Thompson Peter A.director	Sell	59,767	$44.58
May 11, 2026	Thompson Peter A.director	Sell	48,546	$44.61
May 11, 2026	ORBIMED ADVISORS LLCdirector	Sell	184,639	$46.22
May 11, 2026	ORBIMED ADVISORS LLCdirector	Sell	59,767	$44.58
Apr 21, 2026	Thompson Peter A.director	Sell	2,948	$44.52
Apr 21, 2026	Thompson Peter A.director	Sell	52,397	$44.68
Apr 21, 2026	ORBIMED ADVISORS LLCdirector	Sell	52,397	$44.68
Apr 21, 2026	ORBIMED ADVISORS LLCdirector	Sell	2,948	$44.52
Apr 16, 2026	ORBIMED ADVISORS LLCdirector	Sell	47,814	$44.51
Apr 16, 2026	Thompson Peter A.director	Sell	226,906	$45.34
Apr 16, 2026	Thompson Peter A.director	Sell	235,863	$44.64

Source: SION SEC Form 4 filings, latest May 29, 2026. For informational purposes only — not investment advice.

Overview

Sionna Therapeutics, Inc. (NASDAQ:SION) is a clinical-stage biopharmaceutical company founded to develop innovative treatments for cystic fibrosis patients. The company emerged from stealth mode and went public, focusing specifically on creating medicines that restore normal function to the defective protein responsible for cystic fibrosis. Sionna represents a specialized player in the rare disease therapeutics space, dedicating its resources entirely to addressing the underlying molecular defects that cause cystic fibrosis rather than just managing symptoms.

Business

Sionna Therapeutics operates in the rare disease biopharmaceutical sector, specifically targeting cystic fibrosis through a novel therapeutic approach. Cystic fibrosis is a genetic disorder affecting approximately 70,000 people worldwide, caused by mutations in the gene that produces the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This protein normally acts as a chloride channel in cell membranes, but when defective, it leads to thick, sticky mucus buildup in the lungs and digestive system, causing progressive lung damage and infections. The company's core focus is developing CFTR modulators - small molecule drugs designed to correct the underlying protein defect rather than merely treating symptoms. These medicines work by either helping the defective CFTR protein fold properly, increasing its function at the cell surface, or both. This represents a precision medicine approach that targets the root cause of the disease at the molecular level. Unlike traditional cystic fibrosis treatments that focus on airway clearance, antibiotics, and enzyme replacement, Sionna's approach aims to normalize CFTR function, potentially offering more comprehensive disease modification. The company appears to be developing treatments for patients with specific CFTR mutations, as different mutations require different therapeutic strategies. This targeted approach reflects the growing understanding that cystic fibrosis is not a single disease but rather a spectrum of conditions requiring personalized treatment approaches.

Revenue model

As a clinical-stage biopharmaceutical company, Sionna currently generates no revenue from product sales, as evidenced by zero revenue across all reported periods. The company operates on a typical biotech business model where it relies on external funding - including venture capital, public offerings, and potentially strategic partnerships - to finance its research and development activities until its drug candidates reach commercialization. Once Sionna's CFTR modulators receive regulatory approval, the company would generate revenue through pharmaceutical product sales to healthcare systems, specialty pharmacies, and patients. The paying customers would primarily be insurance companies, government health programs, and patients with cystic fibrosis. Given the rare disease nature and the precision medicine approach, these drugs would likely command premium pricing, similar to other CFTR modulators in the market. Several factors could significantly impact Sionna's future profitability. Regulatory approval timelines and success rates represent the primary risk, as clinical trial failures or delays can substantially increase development costs. Competition from established players like Vertex Pharmaceuticals, which already markets several CFTR modulators, could pressure pricing and market share. Manufacturing scale and complexity of small molecule drugs will affect gross margins, while the specialized nature of rare disease marketing requires significant investment in medical affairs and patient access programs. The company's ability to secure favorable reimbursement coverage will be crucial, as cystic fibrosis treatments often require lifelong therapy, making payer acceptance essential for commercial success.

Competitive moat

Sionna's competitive moat appears relatively narrow in the current landscape, facing significant challenges from established competitors. The company operates in a space dominated by Vertex Pharmaceuticals, which has built a substantial moat through multiple approved CFTR modulators, extensive patent protection, deep clinical expertise, and established relationships with the cystic fibrosis community. The company's potential moat would need to come from superior efficacy or safety profiles compared to existing treatments, coverage of CFTR mutations not adequately addressed by current therapies, or novel mechanisms of action that provide differentiated benefits. However, without detailed information about Sionna's specific drug candidates or clinical trial results, it's difficult to assess whether such differentiation exists. Intellectual property protection could provide some defensive positioning, but the CFTR modulator space is already crowded with patents, potentially limiting freedom to operate. The specialized nature of cystic fibrosis drug development does create some barriers to entry, requiring deep disease expertise, specialized clinical trial capabilities, and relationships with cystic fibrosis treatment centers. The primary competitive threats come from Vertex's continued innovation and pipeline expansion, potential biosimilar or generic competition as patents expire, and other biotechnology companies developing next-generation CFTR modulators. Additionally, gene therapy approaches being developed by various companies could potentially offer curative treatments that would disrupt the entire CFTR modulator market. Sionna's ability to establish a sustainable competitive position will largely depend on demonstrating clear clinical advantages and securing strong intellectual property protection for its specific therapeutic approaches.

Risks & safety

Sionna presents moderate financial risk typical of clinical-stage biotechnology companies, with adequate near-term liquidity but ongoing cash burn concerns. • Cash position and runway: $82.7 million in cash and short-term investments as of Q1 2025, down from $37.8 million in Q4 2024, suggesting recent financing activity • Cash burn rate: Quarterly operating cash outflow of $16.3 million in Q1 2025, implying approximately 5 quarters of runway at current burn rate • Debt levels: Minimal debt with debt-to-equity ratio of 0.027, indicating low leverage risk • Liquidity strength: Exceptional current ratio of 28.7x and quick ratio of 28.7x, demonstrating strong short-term solvency • Valuation concerns: Negative book value and complex valuation metrics due to development-stage status and accumulated losses • Operational losses: Consistent quarterly losses of $15-16 million, with annual losses of $62 million in 2024 • Other considerations: No revenue generation creates dependency on capital markets for continued operations; clinical trial outcomes will be critical for future funding access

Recent development

Based on the available financial data, Sionna appears to be in the clinical development phase with consistent research and development spending patterns. The company has maintained relatively stable quarterly operating cash outflows in the $11-16 million range, suggesting steady progress in clinical programs without major pivots or expansions. The significant increase in cash position from $37.8 million in Q4 2024 to $82.7 million in Q1 2025 indicates the company completed a substantial financing round, likely to fund continued clinical development activities. This capital raise suggests investor confidence in the company's clinical programs and provides extended runway for operations. The company's total assets have grown substantially from $51.9 million at the end of 2023 to $369.7 million in Q1 2025, reflecting not only the cash infusion but also potential increases in intellectual property valuations or other intangible assets related to its drug development programs. The consistent focus on CFTR modulator development, as evidenced by steady R&D spending patterns, suggests the company has remained committed to its core therapeutic strategy without major strategic shifts or diversification into other disease areas.

SION company profile · for informational purposes only — not investment advice.

Track SION with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free